Elranatamab/Lenalidomide巩固和/或Elranatamab维持D-VRD诱导后符合移植资格的NDMM患者的护理与护理标准 (ElLen)
对新诊断的多发性骨髓瘤治疗的第3阶段，开放标签，受控的，随机的研究，旨在评估Elranatamab-lenalidomide组合的功效和安全性，作为替代化学疗法的替代，然后在整合阶段进行自体干细胞移植，并与Elranatamab中的Care Pareenandent Care Pareencents相比，
This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT.
824 patients will be enrolled in this study from approximately 70 study sites.
The 2 parts in the Treatment Phase are described below.
Part 1: Induction/ASCT/Consolidation Phase (1:1 Randomization)
After the screening period, patients will be randomly allocated (1:1) to either:
- Arm A (standard of care arm): standard induction therapy with 4 cycles of D-VRd, followed by HDCT (Melphalan) + ASCT, D-VRd consolidation therapy
- Arm B (experimental arm): standard induction therapy with 4 cycles of D-VRd, followed by elranatamab and lenalidomide consolidation therapy.
Part 2: Maintenance Phase (1:1 Re-randomization) Patients will be re-randomized (1:1) and will enter the Maintenance Phase upon completion of consolidation therapy.
• Arm C (standard of care arm): daratumumab + lenalidomide approx 2 years. Subjects with a negative MRD (for at least 12 months) after 24 cycles of daratumumab-lenalidomide will discontinue daratumumab and continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first).
Subjects who did not achieve MRD negativity for at least 12 months after 24 cycles of daratumumab-lenalidomide will continue to receive daratumumab-lenalidomide until:
-
MRD negativity for at least 12 months is reached. Subjects will then continue with lenalidomide monotherapy until disease progression, or study cut-off date (whichever occurs first).
-
Disease progression
-
Or study cut-off date (whichever occurs first).
- Arm D (experimental arm): elranatamab. Approx 2 years. Subjects with a negative MRD (for at least 12 months) after receiving M22 administration of elranatamab will discontinue study treatment with elranatamab.
Subjects who did not achieve MRD negativity for at least 12 months after M22 elranatamab administration will continue to receive elranatamab, every 24 weeks, until MRD negativity for at least 12 months is reached, disease progression, or study cut-off date (whichever occurs first).
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名：Juliette SEON, PharmD
- 电话号码：0140212404
- 邮箱：j.seon@myelome.fr
学习地点
-
-
-
Brussels、比利时、1000
- 尚未招聘
- Institut Jules Bordet
-
Brussels、比利时、1200
- 尚未招聘
- Cliniques Universitaires Saint Luc
-
Charleroi、比利时、6000
- 尚未招聘
- Grand Hopital Charleroi
-
Liège、比利时、4000
- 尚未招聘
- CHU de Liège
-
Yvoir、比利时、5530
- 尚未招聘
- CHU UCL Namur
-
-
-
-
-
Amiens、法国
- 招聘中
- CHU Amiens
-
Angers、法国
- 招聘中
- CHU Angers
-
Annecy、法国
- 招聘中
- Ch Annecy Genevois
-
Argenteuil、法国
- 招聘中
- Centre Hospitalier d'Argenteuil Victor Dupouy
-
Avignon、法国
- 招聘中
- Centre Hospitalier H. Duffaut
-
Bayonne、法国
- 招聘中
- Centre hospitalier de la Côte Basque
-
Besançon、法国
- 招聘中
- CHU Besançon
-
Blois、法国
- 招聘中
- Centre Hospitalier Simone Veil
-
Bobigny、法国
- 招聘中
- Hôpital Avicenne
-
Bordeaux、法国
- 招聘中
- CHU Bordeaux - Hopital Haut Lévêque - Centre F. Magendi
-
Bourg-en-Bresse、法国
- 招聘中
- CH Fleyriat
-
Brest、法国
- 招聘中
- CHRU Brest - Hôpital A. Morvan
-
Caen、法国
- 招聘中
- CHU Caen - Côte de Nacre
-
Chalon-sur-Saône、法国
- 招聘中
- Centre Hospitalier William Morey
-
Chambéry、法国
- 招聘中
- CHMS Centre Hospitalier Métropole Savoie
-
Chartres、法国
- 招聘中
- Hopital Louis Pasteur
-
Clamart、法国
- 招聘中
- Hôpital d'Instruction des Armées Percy
-
Clermont-Ferrand、法国
- 招聘中
- Chu Estaing
-
Corbeil-Essonnes、法国
- 招聘中
- Centre Hospitalier Sud Francilien
-
Créteil、法国
- 招聘中
- CHU Henri Mondor
-
Dijon、法国
- 招聘中
- CHU Dijon
-
Dijon、法国
- 招聘中
- Institut de cancérologie de Bourgogne
-
Dunkirk、法国
- 招聘中
- Centre Hospitalier de Dunkerque
-
Grenoble、法国
- 招聘中
- CHU de Grenoble
-
La Roche-sur-Yon、法国
- 招聘中
- CHD Vendée
-
La Réunion、法国
- 招聘中
- CHU de la Réunion Site SUD (Terre Sainte)
-
Le Havre、法国
- 招聘中
- Hopital Monod
-
Le Mans、法国
- 招聘中
- CH Le mans
-
Lille、法国
- 招聘中
- CHRU Hôpital Claude Huriez
-
Limoges、法国
- 招聘中
- Centre Hospitalier Universitaire (CHU) de Limoges
-
Lyon、法国、69373
- 招聘中
- Centre Léon Bérard
-
Lyon、法国
- 招聘中
- Centre Hospitalier Lyon Sud
-
Meaux、法国
- 招聘中
- Grand Hopital Est Francilien (GHEF) Site de Meaux
-
Metz、法国
- 招聘中
- Hôpital de Mercy (CHR Metz-Thionville)
-
Mont-de-Marsan、法国
- 招聘中
- Centre de Recherche Clinique / GHT des Landes
-
Montpellier、法国
- 招聘中
- Hopital Saint Eloi - CHU Montpellier
-
Mulhouse、法国
- 招聘中
- Hôpital E. Muller
-
Nancy、法国
- 招聘中
- CHRU Hôpitaux de Brabois
-
Nantes、法国
- 招聘中
- CHRU Hôtel Dieu
-
Nice、法国
- 招聘中
- Hôpital Archet 1
-
Nîmes、法国
- 招聘中
- CHU Carémeau, Institut de Cancérologie du Guard
-
Orléans、法国
- 招聘中
- CHR Orléans
-
Paris、法国
- 招聘中
- Hôpital Cochin
-
Paris、法国
- 招聘中
- CHU Hôpital Saint Antoine
-
Paris、法国
- 招聘中
- Hôpital Necker
-
Paris、法国
- 招聘中
- Hôpital Saint Louis
-
Paris、法国
- 招聘中
- La Pitié Salpêtrière
-
Perpignan、法国
- 招聘中
- CH Saint Jean
-
Poitiers、法国
- 招聘中
- CHU Poitiers - Pôle régional de Cancérologie
-
Pontoise、法国
- 招聘中
- Centre hospitalier René Dubost
-
Périgueux、法国
- 招聘中
- Centre Hospitalier de Perigueux
-
Quimper、法国
- 招聘中
- Centre Hospitalier de Quimper Cornouaille
-
Rennes、法国
- 招聘中
- CHRU Hôpital de Pontchaillou
-
Rouen、法国
- 招聘中
- Centre Henri Becquerel
-
Saint-Brieuc、法国
- 招聘中
- Centre Hospitalier Saint Brieuc
-
Saint-Priest、法国
- 招聘中
- Institut de Cancérologie Lucien Neuwirth
-
Saint-Quentin、法国
- 招聘中
- Centre Hospitalier de Saint-Quentin
-
Strasbourg、法国
- 招聘中
- CHU Strasbourg
-
Tarbes、法国
- 招聘中
- Centre hospitalier
-
Toulouse、法国
- 招聘中
- Pôle IUCT Oncopole CHU
-
Tours、法国
- 招聘中
- CHRU Hôpital Bretonneau - Centre Henry Kaplan
-
Vannes、法国
- 招聘中
- CH Bretagne Atlantique Vannes et Auray - P. Chubert
-
Versailles、法国
- 招聘中
- CHV André Mignot - Université de Versailles
-
Villejuif、法国
- 招聘中
- Gustave Roussy
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Male or female subjects, aged over 18 but < 70 years old
-
Patients have provided voluntary written informed consent before performing any study-related procedure.
-
Patients with newly diagnosed multiple myeloma (NDMM) eligible for high-dose chemotherapy (melphalan) and autologous stem cell transplantation (ASCT).
-
Patients with documented symptomatic NDMM according to CRAB and/or SLIM criteria, with measurable disease as defined by:
-
Presence of ≥10% monoclonal plasma cells in the bone marrow OR presence of a biopsy-proven plasmacytoma. In addition, the patient must have ≥1 of the following myeloma defining events:
- Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than upper limits of normal (ULN) or >2.75 mmol/L (>11 mg/dL).
- Renal insufficiency: creatinine clearance < 40mL/min/1.73 m2 using CKD-EPI or serum creatinine >177 μmol/L (>2 mg/dL).
- Anemia: hemoglobin >2 g/dL below the lower limit of normal (LLN) or hemoglobin <10 g/dL.
- Bone lesions: ≥1 osteolytic lesion on skeletal radiography, CT or PET-CT.
- Clonal bone marrow plasma cell percentage ≥60%.
- Serum involved/uninvolved free light chain ratio ≥100.
- More than 1 focal lesion (≥5 mm diameter) on MRI.
-
Measurable disease as defined by serum M-component ≥5 g/L, and/or urine M-component ≥200 mg/24 h and/or serum FLC ≥100 mg/L.
-
-
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
-
Patients must have clinical laboratory values (within 15 days of initiating induction therapy) as follows:
• Hemoglobin ≥7.5 g/dL (≥5 mmol/L). Prior red blood cell (RBC) transfusion or the use of recombinant human erythropoietin is permitted.
• Absolute neutrophil count (ANC) ≥1.0 G/L (granulocyte colony stimulating factor [G-CSF] use is permitted).
• Aspartate aminotransferase (AST) ≤3 x ULN.
• Alanine aminotransferase (ALT) ≤ 3 x ULN.
• Total bilirubin ≤3 x ULN (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, that require a direct bilirubin ≤3 x ULN).
• Calculated creatinine clearance ≥40 mL/min/1.73 m².
- Albumin corrected serum calcium ≤14 mg/dL (<3.5 mmol/L); or free-ionized calcium ≤6.5 mg/dL (≤1.6 mmol/L).
- Platelet count ≥50 Giga/L for subjects who have <50% of bone marrow nucleated cells as plasma cells. If not, platelet count >30 G/L (platelets transfusions done during the 15 days before initiating induction therapy are not permitted).
-
Women of childbearing potential must have a negative serum or urine pregnancy test during the screening period before randomization AND within 3 days before of initiating induction therapy.
-
Patients must be willing and able to comply with scheduled appointments, treatment plan, laboratory tests, and other study procedures (such as blood transfusion if required, ASCT, IVIG prophylaxis, etc.).
Exclusion Criteria:
-
Subjects previously treated with any systemic therapy for multiple myeloma. Patients are allowed corticosteroids before or during screening, as far as the total dose received is not >160 mg of dexamethasone (or equivalent) within 14 days before initiating induction therapy. Patients with concurrent radiotherapy within the 14 days before initiating induction therapy are not eligible (If possible, in these cases, enrolment should be deferred).
-
Subject with ongoing Grade ≥ 3 peripheral sensory or motor neuropathy.
-
Subject with history of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.
-
Subject with a current diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or solitary plasmacytoma.
-
Subject has a diagnosis of Waldenström's macroglobulinemia, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
-
The subject has had plasmapheresis within 14 days of initiating induction therapy.
-
Subject with clinical signs of meningeal involvement of multiple myeloma.
-
The subject has plasma cell leukemia (by WHO criterion: ≥5% of plasma cells in the peripheral blood) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
-
Subject has any concurrent medical or psychiatric condition or disease (e.g., active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.
-
Subject has clinically significant cardiac disease, including:
• Subject has had myocardial infarction within 1 year before initiating induction therapy, or currently has an unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association [NYHA] class III IV).
- Subject has uncontrolled cardiac arrhythmia (common terminology criteria for adverse events [CTCAE] version 4 grade ≥2) or clinically significant electrocardiography (ECG) abnormalities.
- Subject with a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec (12-lead ECG).
-
Subjects taking systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort (millepertuis) within the 14 days before initiating induction therapy.
-
Known intolerance to steroids, mannitol, pregelatinized starch, sodium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study intervention that are not amenable to premedication with steroids and H2 blockers or would prohibit further treatment with these agents.
-
Known allergies to any of the study medications, their analogues, or excipients in the various formulations.
-
Subjects who have had major surgery within 2 weeks before study inclusion (signing of the informed consent) OR will not have fully recovered from surgery before initiating induction therapy OR have surgery planned during their study participation. Kyphoplasty and vertebroplasty are not considered as major surgery.
-
Subjects with any prior or concurrent malignancy (other than multiple myeloma) within 5 years of study inclusion study, except for adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or localized prostate adenocarcinoma diagnosed ≥3 years ago and without evidence of biological failure, or other cancers for which the subject has undergone potentially curative therapy and has without evidence of relapse/recurrence for ≥5 years.
-
Pregnant or breast-feeding women.
Women that refuse to abstain from heterosexual intercourse or refuse to use adequate contraceptives during heterosexual intercourse starting at least 4 weeks before initiating induction therapy and continually until at least 4 weeks after discontinuing lenalidomide,90 days after discontinuing daratumumab and 6 months after discontinuing elranatamab.
18. Men with partners of childbearing potential, even men with a successful vasectomy, that refuse to use a condom during intercourse, from initiating induction therapy to ≥4 weeks ys after discontinuing lenalidomide,. Furthermore, men must agree to not donate sperm during this period.
19. Known positive for HIV or active hepatitis A, B or C: Uncontrolled or active HBV infection: Patients with positive HBsAg and/or HBV DNA
Of note:
Patients can be eligible if anti-HBc IgG positive (with or without positive anti-HBs) but HBsAg and HBV DNA are negative.
o If anti-HBV therapy in relation to prior infection was started before initiation of IMP, the anti-HBV therapy and monitoring should continue throughout the study treatment period.
Patients with negative HBsAg and positive HBV DNA observed during screening period will be evaluated by a specialist for start of anti-viral treatment: study treatment could be proposed if HBV DNA becomes negative, and all the other study criteria are still met.
• Active HCV infection: positive HCV RNA and negative anti-HCV.
Of note:
Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The antiviral therapy for HCV should continue throughout the treatment period until seroconversion.
Patients with positive anti-HCV and undetectable HCV RNA without antiviral therapy for HCV are eligible.
20. Patient with an active systemic infection or severe infections requiring parenteral administration of antibiotics.
21. Patients with a gastrointestinal disease/disorder that may significantly impact the absorption of oral treatments.
22. Patients unable or unwilling to undergo antithrombic prophylaxis.
23. A person under guardianship, trusteeship, or deprived of freedom by a judicial or administrative decision.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：D-VRD induction, ASCT and D-VRD consolidation (arm A)
Standard induction therapy with 4 cycles of D-VRd, followed by HDCT (Melphalan) + ASCT, and 2 cycles of D-VRd consolidation therapy |
In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), and in combination with daratumumab in maintenance (Arm C) Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A ASCT is performed in consolidation for Arm A patients after induction therapy with D-VRD Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A |
|
实验性的：D-VRD induction followed by elranatamab and lenalidomide consolidation (arm B)
Standard induction therapy with 4 cycles of D-VRd, followed by elranatamab and lenalidomide consolidation therapy. |
In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), and in combination with daratumumab in maintenance (Arm C) Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms |
|
有源比较器：daratumumab + lenalidomide maintenance (Arm C)
Daratumumab + Lenalidomide for two years (maintenance) |
In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), and in combination with daratumumab in maintenance (Arm C) Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A |
|
实验性的：elranatamab maintenance (Arm D)
Elranatamab monotherapy for two years (maintenance) |
Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1 (induction/consolidation) from Randomization 1 (R1): to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Minimal Residual Disease (MRD) negativity rate
大体时间：at end of consolidation, up to 36 months
|
To assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of MRD negativity rate. |
at end of consolidation, up to 36 months
|
|
Part 2 (maintenance) from Randomization 2 (R2): to assess whether maintenance therapy with elranatamab is superior to standard of care, in terms of Progression Free Survival (PFS).
大体时间：from the date of second randomization to the date of confirmed PD (IMWG criteria,) or death from any cause, whichever came first, assessed up to 93 monts
|
To assess whether maintenance therapy with elranatamab is superior to standard of care, in terms of PFS. |
from the date of second randomization to the date of confirmed PD (IMWG criteria,) or death from any cause, whichever came first, assessed up to 93 monts
|
|
Key secondary objectives: Part 1 (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior, in terms of PFS
大体时间：PFS defined as the time interval from the date of first randomization to the date of confirmed Progression Disease (IMWG criteria) or death from any cause, whichever occurs first., assessed up to 128 months
|
To assess whether consolidation therapy with elranatamab and lenalidomide is superior, in terms of PFS |
PFS defined as the time interval from the date of first randomization to the date of confirmed Progression Disease (IMWG criteria) or death from any cause, whichever occurs first., assessed up to 128 months
|
|
Key secondary objectives: Part I (induction/consolidation) from R1: to assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of Overal Survival (OS)
大体时间：up to 128 months
|
To assess whether consolidation therapy with elranatamab and lenalidomide is superior to standard of care, in terms of OS |
up to 128 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1 (induction/consolidation) from R1: to assess the efficacy of consolidation therapy with elranatamab and lenalidomide compared to standard of care
大体时间：End of consolidation phase, up to 36 months
|
To assess the efficacy of consolidation therapy with elranatamab and lenalidomide compared to standard of care: Overall response rate (ORR), Very good partial response (VGPR) rate, Complete response (CR) rate |
End of consolidation phase, up to 36 months
|
|
Part 2 (maintenance) from R2: to assess the efficacy of maintenance therapy with elranatamab
大体时间：end of maintenance, up to 58 months
|
To assess the efficacy of maintenance therapy with elranatamab:
|
end of maintenance, up to 58 months
|
|
assess safety & Tolerability during induction, and during consolidation and maintenance therapy: Adverse events (AE), serious Adrverse events (SAE) and And adverse events of special interest (AESI) rates - Incidence of Treatment-Emergent Adverse Events
大体时间：through study completion, up to 128 months
|
To assess safety during induction, and during consolidation and maintenance therapy: AEs, SAE and AESI rates , Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] |
through study completion, up to 128 months
|
|
Throughout the study to evaluate the impact of treatment on health-related Quality of Life (QoL) using Rework questionnaire
大体时间：through study completion, up to 128 months
|
To evaluate the impact of treatment on health-related QoL: Rework questionnaire |
through study completion, up to 128 months
|
|
Part 2 (maintenance) from Randomization 2 (R2): to assess the efficacy of maintenance therapy with elranatamab, Progression Free Survival 2 form Randomization 2
大体时间：up to 128 months
|
To assess the efficacy of maintenance therapy with elranatamab: - PFS of subsequent/next treatment line (PFS2 from R2) |
up to 128 months
|
|
Part 2 (maintenance) from R2: to assess the efficacy of maintenance therapy with elranatamab, in term of Minimal Residual Disease negativity
大体时间：12 months post R2, up to 71 months
|
To assess the efficacy of maintenance therapy with elranatamab: - MRD negativity at 12 months post R2 |
12 months post R2, up to 71 months
|
|
Throughout the study: to evaluate the impact of treatment on health-related Quality of Life (QoL) using EQ-5D-5L
大体时间：Though study completion, an average of 11 years
|
To evaluate the impact of treatment on health-related QoL: scale title :EQ-5D-5L , the minimum value is 0 and maximum value is 100 (100 corresponds to the best health that patient can imagine, 0 corresponds to the worst health that patient can imagine |
Though study completion, an average of 11 years
|
|
Part 2 (maintenance) from R2: To assess the efficacy of maintenance therapy with elranatamab (OS R2)
大体时间：up to 128 months
|
To assess the efficacy of maintenance therapy with elranatamab: - Overall survival from second randomization (OS R2) |
up to 128 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
EXPLORATORY OBJECTIVES: to assess the impact of genomic markers (from Next generation sequencing (NGS) and Whole Genome Sequencing (WGS)) on outcome
大体时间：up to 128 months
|
To assess the impact of genomic markers (from NGS and WGS) on outcome: MRD negativity rate as determined by NGS with a sensitivity of at least 10-5 - PFS1 and OS |
up to 128 months
|
|
EXPLORATORY OBJECTIVES: to assess Immune mechanisms predicting Elra-Len vs ASCT efficacy
大体时间：up to 128 months
|
Impact of the microenvironment (Immune mechanisms predicting Elra-Len vs ASCT efficacy) according to outcome (MRD, PFS and OS) rates |
up to 128 months
|
|
EXPLORATORY OBJECTIVES: to assess the impact of PET imaging parameters/variables on outcome
大体时间：End of consolidation phase, up to 36 months
|
rate of PET imaging positive / negative according to outcome (MRD, PFS and OS) rates |
End of consolidation phase, up to 36 months
|
|
EXPLORATORY OBJECTIVES: To determine influence of M-component measurement assessed by mass spectrometry on outcome
大体时间：up to 128 months
|
To determine influence of M-component measurement assessed by mass spectrometry on outcome |
up to 128 months
|
|
EXPLORATORY OBJECTIVES: To determine influence of circulating tumor cells on outcome in term of PFS1 and OS
大体时间：up to 128 months
|
To determine influence of circulating tumor cells on outcome in term of PFS1 and OS |
up to 128 months
|
|
Exploratory objective :To evaluate the pharmacokinetics (PK) of elranatamab
大体时间：up to 128 months
|
Predose and postdose concentrations of elranatamab |
up to 128 months
|
|
Exploratory objective : To evaluate the immunogenicity of elranatamab
大体时间：up to 128 months
|
To evaluate the immunogenicity of elranatamab |
up to 128 months
|
|
Exploratory objective :To explore correlations between elranatamab exposure and efficacy, safety and biomarker endpoints, if data allow
大体时间：up to 128 months
|
To explore correlations between elranatamab exposure and efficacy, safety and biomarker endpoints, if data allow |
up to 128 months
|
|
exploratory objective : assess treatment discontinuation rates
大体时间：up to 128 months
|
To assess treatment discontinuation rates |
up to 128 months
|
合作者和调查者
合作者
调查人员
- 研究主任：Chanaz LOUNI、The Institute for Functional Medicine
- 首席研究员：Aurore PERROT, Prof、IUCT Toulouse France
- 首席研究员：Cyrille TOUZEAU, Prof、CHU Nantes France
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IFM 2025-01
- 2024-516418-39-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.